Jannsen's Imbruvica Not Cost-Effective, Says NICE
This article was originally published in Scrip
Janssen's Imbruvica (ibrutinib) is not cost-effective for treating NHS patients with chronic lymphocytic leukemia, according to NICE, the health technology appraisal institute for England. But the company intends to challenge the decision, which it says is in "stark contrast" to recommendations in 48 other countries around the world, including Greece.
Register for our free email digests: